Special Issue

Haploidentical Stem Cell Transplantation

Submission Deadline: June 15, 2022 (Open) Submit Now

Guest Editor

Mary A. Slatter, MD

Department of Immunology and BMT, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom;

Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

Website | E-Mail

Research Interests: Transplantation; stem cell transplantation; bone marrow transplantation; hematopoietic stem cells; autoimmunity; cell transplantation

About This Topic

A major barrier to successful Hematopoietic stem cell transplantation has been the availability of HLA-identical donors, only available for 40-75% of eligible patients. An alternative is to use a mismatched or half-matched (haploidentical) related or unrelated donor and deplete the T-lymphocytes in the graft. Historically, the major challenges of using such T-depleted grafts were graft-versus-host disease (GVHD), graft failure, and high transplant-related mortality. A number of new methods of T-depletion are now revolutionising the field. These include use of a replete mismatched graft followed by post-transplant cyclophosphamide which selectively depletes donor alloreactive T-lymphocytes, or in vitro T-depletion using a magnetic column to attract an organic iron bead bound to an antibody to selectively remove T-lymphocytes bearing the αβ T-lymphocyte receptor, associated with GVHD, and retain the γδ T-lymphocyte receptor-bearing cells which confer antiviral and graft-versus-leukemia affects, as well as Natural Killer cells, and lymphocyte precursors. This method also provides a platform for additional cellular therapy such as memory T-lymphocyte add-back, viral specific cytotoxic T-lymphocytes, or mismatched T-lymphocytes with an added caspase suicide gene which can be switched off if GVHD occurs.

In this special issue on Haploidentical Stem Cell Transplantation, submissions related to this topic are invited. Original research or review articles, in adult or pediatric populations are welcome for submission.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Case Report Bilateral Corneal Perforation in a Patient with Chronic Ocular Graft-Versus-Host Disease: A Case Report and Literature Review by Ginevra G Adamo  , Sergio D'Angelo  , Angeli Christy Yu  , Marco Pellegrini  , Federico Bernabei  , Vincenzo Scorcia  and Giuseppe Giannaccare Received: 17 June 2022;  Published: 02 August 2022;  doi: 10.21926/obm.transplant.2203164 Abstract Graft-versus-host disease (GVHD) is a serious complication that may occur in patients receiving allogeneic hematopoietic stem cell transplant (HSCT). GVHD occurs because of the immunological reaction between the donor’s T cells and the recipient’s antigens; GVHD may develop in different tissues, including the eye.